Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Human body

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,354 result(s) found for: Human body. Displaying page 1 of 68.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-001047-67 Sponsor Protocol Number: V503-064 Start Date*: 2025-07-03
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, randomized, placebo-controlled clinical study to evaluate the efficacy, immunogenicity and safety of the 9vHPV vaccine in Japanese males, 16 to 26 years of age.
    Medical condition: Papilloma viral infection
    Disease: Version SOC Term Classification Code Term Level
    27.1 10021881 - Infections and infestations 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2008-008556-16 Sponsor Protocol Number: PRADA Start Date*: 2009-07-13
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Pharmacokinetic and safety study of RAltegravir and atazanavir in a once DAily dose regimen in HIV-1 in-fected patients (PRADA)
    Medical condition: HIV infected patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005786-11 Sponsor Protocol Number: GS-ES-164-0154 Start Date*: 2006-03-28
    Sponsor Name:Gilead Sciences S.L.
    Full Title: Pilot phase IV, multicenter, randomized, open-label and controlled study to assess the evolution of peripheral body fat distribution after switching from AZT containing backbone to Truvada in HIV-1...
    Medical condition: Human Immunodeficiency Virus (HIV-1) infection
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020161 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-001111-39 Sponsor Protocol Number: UMCN-AKF13.03 Start Date*: 2014-12-08
    Sponsor Name:Radboud University Nijmegen Medical Center
    Full Title: Once daily DArunavir/ritonavir in HIV-infected children 6-12 years old: a PHarmacokiNEtic validation of model-based dosing recommendations (DAPHNE)
    Medical condition: HIV infected children treated with darunavir
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10068341 HIV-1 infection LLT
    19.0 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-002183-26 Sponsor Protocol Number: TMC125-C126 Start Date*: Information not available in EudraCT
    Sponsor Name:Tibotec Pharmaceuticals Ltd
    Full Title: A Phase I, open-label trial to investigate pharmacokinetics, safety and tolerability of TMC125 at steady-state in treatment-experienced HIV-1 infected children.
    Medical condition: HIV-1
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020192 HIV-1 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-003955-40 Sponsor Protocol Number: TMC114FD1HTX1004 Start Date*: 2022-05-10
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Single-dose, Open-label, Randomized, Crossover Pivotal Bioequivalence Study in Healthy Participants to Assess the Bioequivalence of Darunavir 600 mg in the Presence of Cobicistat 90 mg When Admin...
    Medical condition: Human Immunodeficiency Virus-1 (Healthy participants)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10020443 Human immunodeficiency virus syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013657-14 Sponsor Protocol Number: AI438006 Start Date*: 2009-11-10
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Randomized, Open label, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068 in HIV-1 Infected Subjects
    Medical condition: HIV-1
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004630-25 Sponsor Protocol Number: TMC114-TiDP29-C228 Start Date*: 2014-02-25
    Sponsor Name:Tibotec Pharmaceuticals
    Full Title: A Phase II, open label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV in combination with low-dose ritonavir (DRV/rtv) in treatment-experienced HIV-1 infect...
    Medical condition: The purpose of this Phase II trial is to evaluate the pharmacokinetics (blood levels), safety and antiviral activity to support dose recommendations by body weight of darunavir with low-dose ritona...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10020192 HIV-1 LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-003459-12 Sponsor Protocol Number: RB-NAIT-01-01 Start Date*: 2020-08-11
    Sponsor Name:Rallybio, IPA, LLC
    Full Title: A Single-blind, Placebo-controlled, Single-center Study Investigating the Dose of Human Anti-Human Platelet Antigen (HPA)-1a Immune Globulin (NAITgam) Needed to Eliminate HPA-1a Positive Platelets ...
    Medical condition: prevention of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT In mothers negative for HPA-1a antigen, fetal platelets positive for HPA-1a antigen, may enter the mother’s circulation and induce pr...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10075151 Fetal and neonatal alloimmune thrombocytopenia LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000725-37 Sponsor Protocol Number: GS-US-183-0149 Start Date*: 2015-02-18
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 1 Study to Evaluate the Bioavailability of Boosted Age-Appropriate Pediatric Elvitegravir (EVG) Tablet or Suspension Formulation Compared with Adult EVG 150 mg Tablets in Healthy Adult Volu...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10020192 HIV-1 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-002830-30 Sponsor Protocol Number: DDD14JRindi Start Date*: 2014-12-24
    Sponsor Name:KU Leuven - Drug Delivery & Disposition
    Full Title: Supersaturation and precipitation of indinavir in the stomach of healthy human volunteers
    Medical condition: Healthy human volunteers (administration of a Protease inhibitor)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004636-29 Sponsor Protocol Number: DDD13DICLO Start Date*: 2014-02-04
    Sponsor Name:KU Leuven - Drug Delivery & Disposition
    Full Title: Supersaturation and precipitation of diclofenac in the stomach of healthy human volunteers
    Medical condition: Healthy human volunteers (administration of a Non-Steroidal Anti-Inflammatory Drug)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003917-29 Sponsor Protocol Number: GS-US-183-0152 Start Date*: 2008-11-11
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Phase 1B Study of the Safety and Pharmacokinetics of Ritonavir-Boosted Elvitegravir (GS-9137/r) Plus a Background Regimen (BR) in HIV-1 Infected, Antiretroviral Treatment-Experienced Adolescents
    Medical condition: Human Innunodeficiency Virus (HIV-1) Infections
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-007086-21 Sponsor Protocol Number: TMC125-TiDP35-C213 Start Date*: 2009-01-23
    Sponsor Name:Tibotec Pharmaceuticals
    Full Title: A Phase II, open-label trial to evaluate the safety, tolerability and antiviral activity of TMC125 in antiretroviral experienced HIV-1 infected children and adolescents.
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) PT (Completed) ES (Completed) FR (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002647-25 Sponsor Protocol Number: TMC278-TiDP6-C215 Start Date*: 2007-12-18
    Sponsor Name:Tibotec Pharmaceuticals
    Full Title: A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhib...
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) PT (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002045-23 Sponsor Protocol Number: GS-US-180-0104 Start Date*: 2008-07-18
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Double-blind, Randomized, Placebo-controlled Phase 1/2 Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9131 in Antiretroviral-Naive, HIV-1 Infected Subjects.
    Medical condition: Antiretroviral treatment–naive subjects chronically infected with HIV-1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003278-34 Sponsor Protocol Number: IRFMN-HIV-6986 Start Date*: 2015-12-02
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: A RANDOMIZED, CROSS-OVER, BIOEQUIVALENCE STUDY OF EFAVIRENZ TABLETS 600 mg OF MYLAN SpA AND SUSTIVA® (EFAVIRENZ) TABLETS 600 mg OF BRISTOL MYERS SQUIBB AT STEADY STATE IN PATIENTS WITH HIV-1
    Medical condition: Patients with HIV-1
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000738-32 Sponsor Protocol Number: TMC114FD1HTX1001 Start Date*: 2022-07-12
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children Aged ≥3 Years and Weighing ≥...
    Medical condition: Human Immunodeficiency Virus-1
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10020443 Human immunodeficiency virus syndrome LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-004631-37 Sponsor Protocol Number: TMC114-TiDP29-C230 Start Date*: 2009-06-25
    Sponsor Name:Tibotec Pharmaceuticals
    Full Title: A Phase II, open-label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV/rtv once daily in treatment-naïve HIV 1 infected adolescents aged between 12 and < 18 ...
    Medical condition: HIV-1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) FR (Completed) ES (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-004728-48 Sponsor Protocol Number: MK-1439-043 Start Date*: 2016-11-23
    Sponsor Name:Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc.
    Full Title: A Study to Evaluate the Comparative Bioavailability of the Investigational Oral Pediatric Minitablet Formulation of MK-1439 Compared to the Adult Formulation of MK-1439 in Healthy Adult Subjects
    Medical condition: HIV – Human Immunodeficiency Virus
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 22 01:08:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA